Progressive supranuclear palsy (PSP) is a neurodegenerative disease alike Parkinson's disease. The disease results from damage to nerve cells in the brain. One of the common symptomof the disease include inability to aim and move the eyes properly, where individuals may experience as blurring of vision. It is a rare brain disorder that affects body movement, control of walking i.e. gait and balance, speech, swallowing, vision, mood and behavior, and thinking.
Market Dynamics
Rising incidence of progressive supranuclear palsy (PSP) is expected to drive progressive supranuclear palsy treatment market growth. For instance, according to the National Institute of Neurological Disorders and Stroke, an article published in July 2020, reports that about 3-6 in every 100,000 people have progressive supranuclear palsy worldwide, and around 20,000 U.S. populace are suffering from progressive supranuclear palsy.
However, lack of identification or diagnosis of progressive supranuclear palsy are expected to hinder the market growth. For instance, according to the National Institute of Neurological Disorders and Stroke, an article published in July 2020, states that currently there are no specific laboratory tests or imaging approaches are definitively diagnose progressive supranuclear palsy.
Key features of the study
• This report provides in-depth analysis of the global progressive supranuclear palsy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global progressive supranuclear palsy treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study are AbbVie Inc., Acorda Therapeutics Inc., Biogen Inc., Bristol-Myers Squibb Co., Merck & Co. Inc., UCB Biopharma, AlzProtect, Asceneuron Therapeutics, TauRx Pharmaceuticals, GlaxoSmithKline PLC, Novartis AG, and Teva Pharmaceutical Industries Ltd. among others
• Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
• The global progressive supranuclear palsy treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global progressive supranuclear palsy treatment market.
Market Segmentation
• By Drug Type (Revenue, USD Mn, 2021-2033)
o Dopamine
o Anticholinergic Agents
o Tricyclic Antidepressants
o Others
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region (Revenue, USD Mn, 2021-2033)
o North America
 U.S.
 Canada
o Latin America
 Brazil
 Mexico
 Argentina
 Rest of Latin America
o Europe
 Germany
 U.K.
 France
 Italy
 Spain
 Russia
 Rest of Europe
o Asia Pacific
 China
 India
 Japan
 Australia
 South Korea
 ASEAN
 Rest of Asia Pacific
o Middle East
 GCC
 Israel
 Rest of Middle East
o Africa
 South Africa
 Central Africa
 North Africa
• Key Players
o AbbVie Inc.
o Acorda Therapeutics Inc.
o Biogen Inc.
o Bristol-Myers Squibb Co.
o Merck & Co. Inc.
o UCB Biopharma
o AlzProtect
o Asceneuron Therapeutics
o TauRx Pharmaceuticals
o GlaxoSmithKline PLC
o Novartis AG
o Teva Pharmaceutical Industries Ltd.

Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
 Market Definition and Scope
o Executive Summary
 Market Snapshot, By Drug Type
 Market Snapshot, By Distribution Channel
 Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
 Drivers
 Restraints
 Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Progressive Supranuclear Palsy Treatment Market, By Drug Type, 2021 – 2033, (USD Million)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022– 2033
 Segment Trends
o Dopamine
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Anticholinergic Agents
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Tricyclic Antidepressants
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Others
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
5. Progressive Supranuclear Palsy Treatment Market, By Distribution Channel, 2021 – 2033, (USD Million)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 – 2033
 Segment Trends
o Hospital Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Retail Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
o Online Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Million)
6. Progressive Supranuclear Palsy Treatment Market, By Region, 2021 – 2033, (USD Million)
o Introduction
 Market Share Analysis, By Region, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, For Regions, 2022–2033
 Regional Trends
o North America
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
 Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
 Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o U.S.
o Canada
o Latin America
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
 Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
 Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
 Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
 Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
 Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
 Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
 Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
 Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o GCC
o Israel
o Rest of Middle East
o Africa
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
 Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
 Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Million)
o North Africa
o Central Africa
o South Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
 AbbVie Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Acorda Therapeutics Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Biogen Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Bristol-Myers Squibb Co.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Merck & Co. Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 UCB Biopharma
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 AlzProtect
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Asceneuron Therapeutics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 TauRx Pharmaceuticals
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 GlaxoSmithKline PLC
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Novartis AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
 Teva Pharmaceutical Industries Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About Us